Loss of imprinting of IGF2 in Ewing's sarcoma.
Insulin-like Growth Factor 2 (IGF2) has recently been demonstrated to be maternally imprinted in both mice and humans. We previously reported loss of imprinting (LOI) of IGF2 in rhabdomyosarcoma (RMS) where IGF2 has been shown to act as an autocrine growth factor and play an important role in pathogenesis. Since IGF2 does not appear to play a role in the pathogenesis of Ewing's sarcoma, we sought to determine whether normal IGF2 imprinting was maintained in these tumors. Of 32 Ewing's tumors examined for imprinting of IGF2, 10 were informative heterozygotes and three of these expressed IGF2 biallelically. Furthermore, all three tumors with LOI and five of seven tumors with normal imprinting transcribed IGF2 mRNA at lower levels while relatively higher levels of IGF2 expression was observed in the remaining two tumors with normal imprinting. These data demonstrate altered imprinting of IGF2 occurs in some Ewing's sarcomas. However, LOI of IGF2 in Ewing's sarcoma was not associated with increased expression of IGF2 mRNA, suggesting that LOI may not be involved in the regulation of IGF2 expression and may be related to genetic or epigenetic abnormalities in tumors independent of IGF2 expression.
Molecular Oncology Section, National Cancer Institute, Bethesda, Maryland 20892-1928, USA.
S
S
Zhan
D N
DN
Shapiro
L J
LJ
Helman
D001483:Base Sequence; D002648:Child; D018392:Genomic Imprinting; D006801:Humans; D007335:Insulin-Like Growth Factor II / Q000235:genetics*; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis; D012512:Sarcoma, Ewing / Q000235:genetics*
D012333:RNA, Messenger; D007335:Insulin-Like Growth Factor II